The goal of Project 2 is to continue to provide the laboratory and preclinical experimental support for the ongoing clinical trials and to develop new ideas for future clinical trial approaches for malignant mesothelioma. The overall hypotheses of this continuing project is that immuno-gene therapy using adoptive T cell transfer can be used to treat malignant mesothelioma successfully, however this will require optimization to augment safety and efficacy. In this renewal, the previous preclinical focus on adenovirus interferon (now successfully being tested in a Phase 2 clinical trial in Project 1) will be redirected toward optimizing adoptively transferred human T-cells that express chimeric antigen receptors (CARs) to support our new and future clinical trials. Adoptive T cell transfer has shown great potential but faces a number of obstacles. Experiments proposed in this Project will focus on increasing trafficking of T cells into tumors, optimizing combination with chemotherapy, and enhancing T cell function by altering the tumor microenvironment and preventing T cell inactivation. Project 3 will explore other issues.
In Specific Aim 1, the approaches and mechanisms of combining blockade of tumor-induced immunosuppression with a cycloxygenase-2 inhibitor with adoptive transfer of CAR-expressing T-cells in mesothelioma will be explored.
In Specific Aim 2, approaches and mechanisms of combining chemotherapy with adoptive transfer therapy will be studied in both in immunodeficient and immunocompetent animal models.
In Specific Aim 3, ways to improve trafficking of CARs will be investigated by genetically altering the T-cells to express new chemokine receptors to enhance T-cell trafficking.
In Specific Aim 4, CAR-expressing T cells will be altered genetically to resist inactivation within the tumor by inhibiting the function of key inhibitory enzymes with an initial focus on SHP-1. Completion of these aims will: 1) provide key preclinical translational studies that can be rapidly applied to our evolving mesothelioma clinical trials in Project 1, 2) advance the entire field of adoptive T cell transfer by overcoming key obstacles, and 3) generate new knowledge about tumor immunology (especially in vivo human T cell biology).

Public Health Relevance

Malignant mesothelioma is currently considered incurable. Transfusing genetically altered anti-tumor lymphocytes is a promising new approach. This project is testing methods to improve the killing ability of these anti-tumor lymphocytes by combining them with other drugs or by finding ways to increase their ability to traffic into tumors and avoid being inactivated within the tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066726-17
Application #
8677699
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
17
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clin Cancer Res 22:3791-800
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Wang, Enxiu; Wang, Liang-Chuan; Tsai, Ching-Yi et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res 3:815-26
Frigault, Matthew J; Lee, Jihyun; Basil, Maria Ciocca et al. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356-67
Lo, Albert; Wang, Liang-Chuan S; Scholler, John et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 75:2800-10
Liu, Xiaojun; Jiang, Shuguang; Fang, Chongyun et al. (2015) Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res 75:3596-607

Showing the most recent 10 out of 82 publications